Literature DB >> 25539599

Association of von Willebrand factor blood levels with exercise hypertension.

Sonja B Nikolic1, Murray J Adams, Petr Otahal, Lindsay M Edwards, James E Sharman.   

Abstract

PURPOSE: A hypertensive response to moderate intensity exercise (HRE) is associated with increased cardiovascular risk. The mechanisms of an HRE are unclear, although previous studies suggest this may be due to haemostatic and/or haemodynamic factors. We investigated the relationships between an HRE with haemostatic and hemodynamic indices.
METHODS: Sixty-four participants (57 ± 10 years, 71 % male) with indication for exercise stress testing underwent cardiovascular assessment at rest and during moderate intensity exercise, from which 20 participants developed an HRE (defined as moderate exercise systolic BP ≥ 170 mmHg/men and ≥ 160 mmHg/women). Rest, exercise and post-exercise blood samples were analysed for haemostatic markers, including von Willebrand factor (vWf), and haemodynamic measures of brachial and central blood pressure (BP), aortic stiffness and systemic vascular resistance index (SVRi).
RESULTS: HRE participants had higher rest vWf compared with normotensive response to exercise (NRE) participants (1,927 mU/mL, 95 % CI 1,240-2,615, vs. 1,129 mU/mL, 95 % CI 871-1,386; p = 0.016). vWf levels significantly decreased from rest to post-exercise in HRE participants (p = 0.005), whereas vWf levels significantly increased from rest to exercise in NRE participants (p = 0.030). HRE participants also had increased triglycerides, rest BP, aortic stiffness and exercise SVRi (p < 0.05 for all). Rest vWf predicted exercise brachial systolic BP (β = 0.220, p = 0.043; adjusted R (2) = 0.451, p < 0.001) independent of age, sex, body mass index, triglycerides, rest brachial systolic BP and aortic stiffness.
CONCLUSIONS: Increased rest blood levels of vWf are independently associated with moderate intensity exercise systolic BP. These findings implicate abnormalities in haemostasis as a possible factor contributing to HRE at moderate intensity.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25539599     DOI: 10.1007/s00421-014-3087-3

Source DB:  PubMed          Journal:  Eur J Appl Physiol        ISSN: 1439-6319            Impact factor:   3.078


  26 in total

1.  A new impedance cardiograph device for the non-invasive evaluation of cardiac output at rest and during exercise: comparison with the "direct" Fick method.

Authors:  A Charloux; E Lonsdorfer-Wolf; R Richard; E Lampert; M Oswald-Mammosser; B Mettauer; B Geny; J Lonsdorfer
Journal:  Eur J Appl Physiol       Date:  2000-07       Impact factor: 3.078

2.  Validation of the Omron HEM-907 device for blood pressure measurement.

Authors:  Mohamed A El Assaad; Jirar A Topouchian; Bernadette M Darné; Roland G Asmar
Journal:  Blood Press Monit       Date:  2002-08       Impact factor: 1.444

3.  Expert consensus document on arterial stiffness: methodological issues and clinical applications.

Authors:  Stephane Laurent; John Cockcroft; Luc Van Bortel; Pierre Boutouyrie; Cristina Giannattasio; Daniel Hayoz; Bruno Pannier; Charalambos Vlachopoulos; Ian Wilkinson; Harry Struijker-Boudier
Journal:  Eur Heart J       Date:  2006-09-25       Impact factor: 29.983

4.  Pulse wave analysis is a reproducible technique for measuring central blood pressure during hemodynamic perturbations induced by exercise.

Authors:  David J Holland; Julian W Sacre; Sarah J McFarlane; Jeffrey S Coombes; James E Sharman
Journal:  Am J Hypertens       Date:  2008-08-21       Impact factor: 2.689

5.  Recommendations for blood pressure measurement in humans and experimental animals: part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research.

Authors:  Thomas G Pickering; John E Hall; Lawrence J Appel; Bonita E Falkner; John Graves; Martha N Hill; Daniel W Jones; Theodore Kurtz; Sheldon G Sheps; Edward J Roccella
Journal:  Circulation       Date:  2005-02-08       Impact factor: 29.690

Review 6.  Exercise-induced hypertension, cardiovascular events, and mortality in patients undergoing exercise stress testing: a systematic review and meta-analysis.

Authors:  Martin G Schultz; Petr Otahal; Verity J Cleland; Leigh Blizzard; Thomas H Marwick; James E Sharman
Journal:  Am J Hypertens       Date:  2012-12-27       Impact factor: 2.689

7.  Validation of a generalized transfer function to noninvasively derive central blood pressure during exercise.

Authors:  James E Sharman; Richard Lim; Ahmad M Qasem; Jeff S Coombes; Malcolm I Burgess; Jeff Franco; Paul Garrahy; Ian B Wilkinson; Thomas H Marwick
Journal:  Hypertension       Date:  2006-05-01       Impact factor: 10.190

8.  Partial blockade of nitric oxide synthase blunts the exercise-induced increase of von Willebrand factor antigen and of factor VIII in man.

Authors:  B Jilma; E Dirnberger; H G Eichler; B Matulla; L Schmetterer; S Kapiotis; W Speiser; O F Wagner
Journal:  Thromb Haemost       Date:  1997-10       Impact factor: 5.249

9.  Validation of the A&D UM-101 professional hybrid device for office blood pressure measurement according to the International Protocol.

Authors:  George S Stergiou; Periklis P Giovas; Charilaos P Gkinos; Dimitris G Tzamouranis
Journal:  Blood Press Monit       Date:  2008-02       Impact factor: 1.444

10.  Moderate-intensity exercise suppresses platelet activation and polymorphonuclear leukocyte interaction with surface-adherent platelets under shear flow in men.

Authors:  Jong-Shyan Wang; Chang-Hui Liao
Journal:  Thromb Haemost       Date:  2004-03       Impact factor: 5.249

View more
  2 in total

1.  Aortic-to-brachial artery stiffness gradient is not blood pressure independent.

Authors:  Matthew K Armstrong; Martin G Schultz; Dean S Picone; James E Sharman
Journal:  J Hum Hypertens       Date:  2019-01-10       Impact factor: 3.012

Review 2.  Von Willebrand disease in the elderly: clinical perspectives.

Authors:  John Chapin
Journal:  Clin Interv Aging       Date:  2018-08-31       Impact factor: 4.458

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.